rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VRTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus
      Nov 18Yahoo FinanceVRTX
      Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
      Nov 17Yahoo FinanceVRTX
      Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
      Nov 13BenzingaVRTX
      Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
      Nov 11Yahoo FinanceVRTX
      What Will Decide Vertex Stock Over The Next Six Months?
      Nov 11Yahoo FinanceVRTX
      Vertex Earnings Call Signals Broad-Based Growth Ahead

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Nov 10The Globe and MailVRTX
      Here is Why Growth Investors Should Buy Vertex (VERX) Now
      Nov 9Yahoo FinanceVERXVRTX
      The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation | The Motley Fool

      These are among the best the industry has to offer.

      Nov 8The Motley FoolVRTX
      Missed Vertex Pharmaceuticals' Run? What Holders Had To Believe
      Nov 8Yahoo FinanceVRTX
      Vertex Pharmaceuticals: Costs Now Outgrow Sales, And Price Needs A Second Vertex

      Vertex Pharmaceuticals is rated Sell, with fair value estimated at $398.25 versus a $530.76 share price. Read more on VRTX stock here.

      Nov 6Seeking AlphaVRTX
      Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.
      Nov 5WSJVRTX
      Vertex Pharmaceuticals Inc (VRTX) Q3 2026 Earnings Call Highlights: Revenue Up 12% as CF, ...
      Nov 4Yahoo FinanceVRTX
      Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Idexx Laboratories (IDXX)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Nov 4The Globe and MailIDXXVRTX
      Vertex Pharmaceuticals earnings analysis: questions answered and next catalysts

      Investing.com -- Vertex Pharmaceuticals (VRTX) rose about 1.2% pre-market to $560 as of Nov 3, 9:27 AM EST. It then reversed. At 12:50 PM EST the stock was at $533.24 (-3.60%), below the prior close of $553.15. Analysts mostly raised price targets, so the selloff looks like profit-taking near the 52-week high of $568.67 rather than a rejection of the results.

      Nov 3Yahoo FinanceVRTX
      Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion
      Nov 3Yahoo FinanceVRTX
      Vertex, ahead of FDA decision, calms fears surrounding kidney drug
      Nov 3Yahoo FinanceVRTX
      Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says
      Nov 3Yahoo FinanceVRTX
      Why is Vertex Pharmaceuticals stock rallying today?
      Nov 3Investing.comVRTX
      Vertex Pharmaceuticals Incorporated Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceVRTX
      Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results
      Nov 3BenzingaVRTX
      Vertex: 3 Key Takeaways for Long-Term Investors
      Nov 3Yahoo FinanceVRTX
      Should Strong Q3 Revenue Require Action From Vertex Pharmaceuticals (VRTX) Investors?
      Nov 3Yahoo FinanceVRTX
      Vertex: Q3 Earnings Snapshot

      BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter profit of $653.

      Nov 3Yahoo FinanceVRTX
      Vertex Pharmaceuticals Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceVRTX
      Vertex Q3 2026 slides: revenue up 12%, nephrology launch imminent
      Nov 2Investing.comVRTX
      Vertex raises 2026 revenue guidance following mixed Q3 results

      Vertex lifts 2026 revenue guidance after Q3 results. Read more here.

      Nov 2Seeking AlphaVRTX
      Vertex Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 2BenzingaVRTX
      Why is Vertex Pharmaceuticals stock climbing today?
      Nov 2Investing.comVRTX
      Vertex, In A Buy Zone, Wavers On Mixed Report, Light Guide

      Vertex stock yo-yoed on its third-quarter report late Monday after earnings came up short and full-year guidance missed views.

      Nov 2Investor's Business DailyVRTX
      Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Nov 2The Globe and MailVRTX
      Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
      Nov 2MarketWatchKRYSVRTX
      Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Nov 2Yahoo FinanceVRTX
      Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction | The Motley Fool

      Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.

      Nov 2The Motley FoolVRTX
      Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates
      Nov 2Yahoo FinanceVRTX
      Vertex Reports Third Quarter 2026 Financial Results
      Nov 2Yahoo FinanceVRTX
      Vertex Pharmaceuticals (VRTX) Stock May Still Have Value Following A 190% Run

      Vertex Pharmaceuticals has delivered a strong multi year share price run, and the question now is whether that climb can be backed up by the cash the business is expected to generate. With a Discounted Cash Flow (DCF) framework available, the focus turns to how that share history lines up with the intrinsic value implied by its future cash streams. Over the past 5 years, Vertex Pharmaceuticals has returned 189.9% which puts real weight on whether the current valuation can be supported by the...

      Nov 1Yahoo FinanceVRTX
      Vertex Pharmaceuticals earnings: what to look for from VRTX

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Nov 1The Globe and MailVRTX
      Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update?
      Oct 31Yahoo FinanceVRTX
      Vertex Pharmaceuticals stock hits all-time high at 560.99 USD
      Oct 30Investing.comVRTX
      Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
      Oct 29BenzingaVRTX
      Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
      Oct 28Yahoo FinanceVRTX
      Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
      Oct 28Yahoo FinanceVRTX
      Citi Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailVRTX
      Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue | The Motley Fool

      Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.

      Oct 27The Motley FoolVRTX
      Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
      Oct 26Yahoo FinanceVRTX
      Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
      Oct 26MarketWatchVRTX
      Vertex Pharmaceuticals shares may move 4.3% on earnings
      Oct 26Investing.comVRTX
      ETFs Are Net Sellers of Vertex Pharmaceuticals (VRTX) on Oct. 22
      Oct 26Yahoo FinanceVRTX
      Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept
      Oct 25Yahoo FinanceVRTX
      What Vertex Pharmaceuticals Holders Bought Into

      If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into endocrinology, yet none of that was visible at the October 2025 starting line. The real question is whether early conviction around diversified gene editing and new therapies was the key...

      Oct 25Yahoo FinanceVRTX

      This is the newest page. Registered accounts read further back.